Brain Health: Translating Scientific Evidence Into Clinical Practice in Multiple Sclerosis
Brain volume loss (BVL) progresses more rapidly in patients with multiple sclerosis (MS) than in healthy individuals, and brain atrophy begins early in the course of the disease. The objective of this symposium was to emphasise the importance of care and preservation of the brain within treatment pr...
Main Authors: | , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
European Medical Journal
2016-07-01
|
Series: | European Medical Journal Neurology |
Subjects: | |
Online Access: | http://emjreviews.com/wp-content/uploads/Brain-Health-Translating-Scientific-Evidence-Into-Clinical-Practice-in-Multiple-Sclerosis.pdf |
id |
doaj-87d5153c102e43039b58cf506ce4fd7f |
---|---|
record_format |
Article |
spelling |
doaj-87d5153c102e43039b58cf506ce4fd7f2020-11-24T23:10:34ZengEuropean Medical JournalEuropean Medical Journal Neurology2054-45292016-07-01413644 Brain Health: Translating Scientific Evidence Into Clinical Practice in Multiple SclerosisPer Soelberg Sørensen0Wiendl1Andreas Lysandropoulos,2Andrew Chan3Danish Multiple Sclerosis Center, Copenhagen University Hospital, Copenhagen, Denmark Department of Neurology, University Hospital of Münster, Münster, Germany Neuroimmunology Unit, Department of Neurology, University Hospital Erasme, Brussels, Belgium Department of Neurology, St. Josef-Hospital, Ruhr-University Bochum, Bochum, GermanyBrain volume loss (BVL) progresses more rapidly in patients with multiple sclerosis (MS) than in healthy individuals, and brain atrophy begins early in the course of the disease. The objective of this symposium was to emphasise the importance of care and preservation of the brain within treatment protocols for MS so that early and appropriate management can be initiated to preserve brain volume and function. Prof Per Solberg Sørensen chaired the symposium and welcomed the speakers. Prof Heinz Wiendl gave a presentation on BVL in MS and described its underlying pathophysiology. Dr Andreas Lysandropoulos illustrated how information on BVL is clinically relevant and can be taken from clinical studies to assist clinical practice and decision-making. The final presentation was given by Prof Andrew Chan who highlighted the important role of brain atrophy in decision-making for early treatment and presented recent data for two treatments for MS: teriflunomide and the monoclonal antibody alemtuzumab. The symposium was concluded by a short question and answer session.http://emjreviews.com/wp-content/uploads/Brain-Health-Translating-Scientific-Evidence-Into-Clinical-Practice-in-Multiple-Sclerosis.pdfEANEuropean Association of Neurology |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Per Soelberg Sørensen Wiendl Andreas Lysandropoulos, Andrew Chan |
spellingShingle |
Per Soelberg Sørensen Wiendl Andreas Lysandropoulos, Andrew Chan Brain Health: Translating Scientific Evidence Into Clinical Practice in Multiple Sclerosis European Medical Journal Neurology EAN European Association of Neurology |
author_facet |
Per Soelberg Sørensen Wiendl Andreas Lysandropoulos, Andrew Chan |
author_sort |
Per Soelberg Sørensen |
title |
Brain Health: Translating Scientific Evidence Into Clinical Practice in Multiple Sclerosis |
title_short |
Brain Health: Translating Scientific Evidence Into Clinical Practice in Multiple Sclerosis |
title_full |
Brain Health: Translating Scientific Evidence Into Clinical Practice in Multiple Sclerosis |
title_fullStr |
Brain Health: Translating Scientific Evidence Into Clinical Practice in Multiple Sclerosis |
title_full_unstemmed |
Brain Health: Translating Scientific Evidence Into Clinical Practice in Multiple Sclerosis |
title_sort |
brain health: translating scientific evidence into clinical practice in multiple sclerosis |
publisher |
European Medical Journal |
series |
European Medical Journal Neurology |
issn |
2054-4529 |
publishDate |
2016-07-01 |
description |
Brain volume loss (BVL) progresses more rapidly in patients with multiple sclerosis (MS) than in healthy individuals, and brain atrophy begins early in the course of the disease. The objective of this symposium was to emphasise the importance of care and preservation of the brain within treatment protocols for MS so that early and appropriate management can be initiated to preserve brain volume and function.
Prof Per Solberg Sørensen chaired the symposium and welcomed the speakers. Prof Heinz Wiendl gave a presentation on BVL in MS and described its underlying pathophysiology. Dr Andreas Lysandropoulos illustrated how information on BVL is clinically relevant and can be taken from clinical studies to assist clinical practice and decision-making. The final presentation was given by Prof Andrew Chan who highlighted the important role of brain atrophy in decision-making for early treatment and presented recent data for two treatments for MS: teriflunomide and the monoclonal antibody alemtuzumab. The symposium was concluded by a short question and answer session. |
topic |
EAN European Association of Neurology |
url |
http://emjreviews.com/wp-content/uploads/Brain-Health-Translating-Scientific-Evidence-Into-Clinical-Practice-in-Multiple-Sclerosis.pdf |
work_keys_str_mv |
AT persoelbergsørensen brainhealthtranslatingscientificevidenceintoclinicalpracticeinmultiplesclerosis AT wiendl brainhealthtranslatingscientificevidenceintoclinicalpracticeinmultiplesclerosis AT andreaslysandropoulos brainhealthtranslatingscientificevidenceintoclinicalpracticeinmultiplesclerosis AT andrewchan brainhealthtranslatingscientificevidenceintoclinicalpracticeinmultiplesclerosis |
_version_ |
1725606645551071232 |